Exelixis Inc at Goldman Sachs Healthcare Conference Transcript
All right. It looks like we're started. Thanks, everyone, for joining. I'm Stephen Sloan, an analyst on the biopharma research team here at Goldman. And I'm happy to present or do a fireside chat with Exelixis. We have Andrew Peters here, Senior Vice President and Head of Strategy. I know on the schedule it said Michael Morrissey, but we have Andrew Peters, which we're very happy to host.
And so to kick this off, for those of you who might not be as familiar with Andrew, do you want to give a bit of background on yourself? This is very much in line with what Chris Shibutani would be doing. So let's kick it off here.
Yes. No, happy to be here. Thanks for the invite. And before I begin, likely to be making some forward-looking statements today. So please see our relevant SEC filings for appropriate disclosures about the risk to our business, et cetera.
So yes, so I've been at Exelixis since about 2018 or so
Access to All Earning Calls and Stock Analysis | |
30-Year Financial on one screen | |
All-in-one Stock Screener with unlimited filters | |
Customizable Stock Dashboard | |
Real Time Insider Trading Transactions | |
8,000+ Institutional investors’ 13F holdings | |
Powerful Excel Add-in and Google sheets Add-on | |
All data downloadable | |
Quick customer support | |
And much more... |